Arthur Allen

Author's posts

How Little Denmark Got Homegrown Giant Novo Nordisk To Lower Ozempic Prices

As Congress pushes for Medicare to cover payment for anti-obesity drugs, Denmark — Ozempic maker Novo Nordisk’s home — has limited coverage of the drug after cost overruns “emptied all the money boxes in the entire public health system.”

Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs

Although Novo Nordisk and Lilly lump together the pharmacies that compound semaglutide and tirzepatide with internet cowboys selling fake drugs, there is a distinction. The FDA has offered Americans little clarity about the vast gray and black markets for the drugs.

The Chicken and Egg Problem of Fighting Another Flu Pandemic

The spread of an avian flu virus in cattle has again brought public health attention to the potential for a global pandemic. Fighting it would depend, for now, on 1940s technology that makes vaccines from hens’ eggs.

Amgen Plows Ahead With Costly, Highly Toxic Cancer Dosing Despite FDA Challenge

The FDA told Amgen to test whether a quarter-dose of its lung cancer drug worked as well as the amount recommended on the product label. It did and with fewer side effects. But Amgen is sticking to the higher dose — which earns it an additional $180,000 a year per patient.

Overdosing on Chemo: A Common Gene Test Could Save Hundreds of Lives Each Year

The FDA and some oncologists have resisted efforts to require a quick, cheap gene test that could prevent thousands of deaths from a bad reaction to a common cancer drug.

Why Covid Patients Who Could Most Benefit From Paxlovid Still Aren’t Getting It

Price worries, bureaucratic obstacles, and “I’m-over-covid-itis” slow uptake of a drug that’s complicated to take but often effective.

A new test could save arthritis patients time, money and pain. But will it be used?

Stories of chronic pain, drug-hopping, and insurance meddling are all too common among patients with rheumatoid arthritis. Precision medicine offers new hope.

A New Test Could Save Arthritis Patients Time, Money, and Pain. But Will It Be Used?

Stories of chronic pain, drug-hopping, and insurance meddling are all too common among patients with rheumatoid arthritis. Precision medicine offers new hope.

Biden Administration’s Limit on Drug Industry Middlemen Backfires, Pharmacists Say

A rule taking effect Jan. 1 was intended to stop one set of abuses by pharmacy benefit managers, or PBMs, but some pharmacists say it’s enabling these price brokers to simply do new things unfairly.

Save Billions or Stick With Humira? Drug Brokers Steer Americans to the Costly Choice

Thousands of patients with autoimmune diseases who rely on Humira, with a list price of $6,600 a month, could get financial relief from new low-cost rivals. So far, the pharmacy benefit managers that control drug prices in America have not delivered on those savings.